SSR181507, a dopamine D2 receptor and 5-HT1A receptor ligand: Evidence for mixed anxiolytic- and antidepressant-like activities

Pharmacology Biochemistry and Behavior

Volumn 97, Issue 3, 2011, Pages 428-435

  Boulay, Denis ^a   Depoortere, Ronan ^b   Louis, Caroline ^c   Lacave, Martine ^a   Lucas, Marie Thérèse ^a   Griebel, Guy ^a  

^a SANOFI   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

5 HT1A receptor; Antidepressant; Anxiolytic; Atypical antipsychotic; Chronic administration; DA D2 receptor; Passive avoidance; Social interaction; SSR181507; Ultrasonic vocalization

Indexed keywords

(3 EXO) 8 BENZOYL N [[7 CHLORO 2,3 DIHYDRO 1,4 BENZODIOXIN 1 YL]METHYL] 8 AZABICYCLO[3.2.1]OCTANE 3 METHANAMINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BUSPIRONE; CLOZAPINE; DIAZEPAM; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUOXETINE; HALOPERIDOL; OLANZAPINE; SEROTONIN 1A AGONIST; SSR 181507; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG ACTIVITY; LATENT PERIOD; MALE; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RAT; SHOCK; SOCIAL INTERACTION; TRANQUILIZING ACTIVITY;

ANIMAL COMMUNICATION; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DIOXANES; LIGANDS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; TROPANES;

ANIMALIA; RATTUS;

EID: 78049495298     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.09.019     Document Type: Article

References (58)

1. A.I. Abbas, P.B. Hedlund, X.P. Huang, T.B. Tran, H.Y. Meltzer, and B.L. Roth Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo Psychopharmacology (Berl) 205 2009 119 128
2. J.E. Alpert, D.A. Franznick, S.B. Hollander, and M. Fava Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder J Clin Psychiatry 65 2004 1069 1075
3. W. An der Heiden, and H. Hafner The epidemiology of onset and course of schizophrenia Eur Arch Psychiatry Clin Neurosci 250 2000 292 303 (Pubitemid 32002383)
4. A.L. Auclair, M.S. Kleven, C. Barret-Grevoz, M. Barreto, A. Newman-Tancredi, and R. Depoortere Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys Behav Brain Res 203 2009 288 295
5. T.R. Barnes, D.A. Curson, P.F. Liddle, and M. Patel The nature and prevalence of depression in chronic schizophrenic in-patients Br J Psychiatry 154 1989 486 491 (Pubitemid 19105228)
6. G.D. Bartoszyk Anxiolytic effects of dopamine receptor ligands: I. Involvement of dopamine autoreceptors Life Sci 62 1998 649 663 (Pubitemid 28045572)
7. P. Blier, and N.M. Ward Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 53 2003 193 203 (Pubitemid 36135929)
8. W.V. Bobo, and R.C. Shelton Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data Expert Opin Pharmacother 10 2009 2145 2159
9. D. Boulay, R. Depoortere, C. Louis, G. Perrault, G. Griebel, and P. Soubrie SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats Neuropharmacology 46 2004 1121 1129 (Pubitemid 38529936)
10. L.A. Bruins Slot, M.S. Kleven, and A. Newman-Tancredi Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat Neuropharmacology 49 2005 996 1006 (Pubitemid 41503299)
11. L.A. Bruins Slot, V.L. De, A. Newman-Tancredi, and D. Cussac Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase Eur J Pharmacol 534 2006 63 70 (Pubitemid 43384184)
12. L.A. Bruins Slot, L. Bardin, A.L. Auclair, R. Depoortere, and A. Newman-Tancredi Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice Behav Pharmacol 19 2008 145 152 (Pubitemid 351365692)
13. R.W. Buchanan, J. Kreyenbuhl, J.M. Zito, and A. Lehman Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia Am J Psychiatry 159 2002 1035 1043 (Pubitemid 34586951)
14. P.F. Buckley, B.J. Miller, D.S. Lehrer, and D.J. Castle Psychiatric comorbidities and schizophrenia Schizophr Bull 35 2009 383 402
15. M.G. Budden A comparative study of haloperidol and diazepam in the treatment of anxiety Curr Med Res Opin 5 1979 759 765 (Pubitemid 9132407)
16. C.B. Caldwell, and I.I. Gottesman Schizophrenics kill themselves too: a review of risk factors for suicide Schizophr Bull 16 1990 571 589
17. P. Celada, M. Puig, M. margos-Bosch, A. Adell, and F. Artigas The therapeutic role of 5-HT1A and 5-HT2A receptors in depression J Psychiatry Neurosci 29 2004 252 265 (Pubitemid 39185866)
18. R.E. Clark, S.J. Bartels, T.A. Mellman, and W.J. Peacock Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy Schizophr Bull 28 2002 75 84 (Pubitemid 34534751)
19. Y. Claustre, D.D. Peretti, P. Brun, C. Gueudet, N. Allouard, R. Alonso, J. Lourdelet, A. Oblin, G. Damoiseau, D. Francon, M.F. Suaud-Chagny, R. Steinberg, M. Sevrin, H. Schoemaker, P. George, P. Soubrie, and B. Scatton SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile Neuropsychopharmacology 28 2003 2064 2076 (Pubitemid 37468175)
20. C. Cohen, G. Perrault, Y. Claustre, O. Curet, G. Griebel, R. Depoortere, and J. Lourdelet Pharmacological characterization of the selective 5-HT1a receptor inverse agonist SL88.0338-08 Soc Neurosciences abst 24 1998 1364
21. C. Cosi, E. Carilla-Durand, M.B. Assie, A.M. Ormiere, M. Maraval, N. Leduc, and A. Newman-Tancredi Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release Eur J Pharmacol 535 2006 135 144
22. J. De Vry, U. Benz, R. Schreiber, and J. Traber Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs Eur J Pharmacol 249 1993 331 339 (Pubitemid 23334108)
23. R. Depoortere, D. Boulay, G. Perrault, O. Bergis, M. Decobert, D. Francon, M. Jung, J. Simiand, P. Soubrie, and B. Scatton SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity Neuropsychopharmacology 28 2003 1889 1902 (Pubitemid 37412100)
24. R. Depoortere, A.L. Auclair, L. Bardin, S.L. Bruins, M.S. Kleven, F. Colpaert, B. Vacher, and A. Newman-Tancredi F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms Br J Pharmacol 151 2007 266 277 (Pubitemid 46763037)
25. S.E. File, and J.R. Hyde Can social interaction be used to measure anxiety? Br J Pharmacol 62 1978 19 24 (Pubitemid 8251893)
26. S.E. File, and P. Seth A review of 25 years of the social interaction test Eur J Pharmacol 463 2003 35 53 (Pubitemid 36205071)
27. C. Grant, J. Addington, D. Addington, and C. Konnert Social functioning in first- and multiepisode schizophrenia Can J Psychiatry 46 2001 746 749 (Pubitemid 33127090)
28. M.F. Green, K.H. Nuechterlein, J. Ventura, and J. Mintz The temporal relationship between depressive and psychotic symptoms in recent-onset schizophrenia Am J Psychiatry 147 1990 179 182 (Pubitemid 20060469)
29. G. Griebel 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research Pharmacol Ther 65 1995 319 395
30. 1A receptor blockers as potential drug candidates for the treatment of anxiety disorders Drug News Perspect 1999 484 490
31. S.H. Kennedy, and R.W. Lam Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics Bipolar Disord 5 Suppl 2 2003 36 47 (Pubitemid 38444336)
32. S.W. Kim, I.S. Shin, J.M. Kim, S.H. Lee, J.H. Lee, B.H. Yoon, S.J. Yang, M.Y. Hwang, and J.S. Yoon Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial Prog Neuropsychopharmacol Biol Psychiatry 31 2007 1504 1509 (Pubitemid 47307407)
33. H. Kleinlogel The rat paradoxical sleep as a pharmacological test model W.M. Herrmann, EEG in Drug Research Gustave Fisher 1982 Stuttgart 75 88
34. M.S. Kleven, C. Barret-Grevoz, S.L. Bruins, and A. Newman-Tancredi Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats Neuropharmacology 49 2005 135 143 (Pubitemid 40933752)
35. P.S. Masan Atypical antipsychotics in the treatment of affective symptoms: a review Ann Clin Psychiatry 16 2004 3 13 (Pubitemid 40029199)
36. R.H. McAllister-Williams, and I.N. Ferrier Rapid tranquillisation: time for a reappraisal of options for parenteral therapy Br J Psychiatry 180 2002 485 489 (Pubitemid 34596797)
37. R. McIntyre, and M. Katzman The role of atypical antipsychotics in bipolar depression and anxiety disorders Bipolar Disord 5 Suppl 2 2003 20 35 (Pubitemid 38444335)
38. M.M. Mensonides-Harsema, Y. Liao, H. Bottcher, G.D. Bartoszyk, H.E. Greiner, J. Harting, B.P. de, and H.V. Wikstrom Synthesis and in vitro and in vivo functional studies of ortho-substituted phenylpiperazine and N-substituted 4-N-(o-methoxyphenyl)aminopiperidine analogues of WAY100635 J Med Chem 43 2000 432 439 (Pubitemid 30102083)
39. M.J. Millan Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors J Pharmacol Exp Ther 295 2000 853 861
40. M.J. Millan, M. Brocco, A. Gobert, R. Schreiber, and A. Dekeyne S-16924 [(R)-2-[1-[2-(2, 3-dihydro-benzo[1, 4]dioxin-5-yloxy)-ethyl]- pyrrolidin-3yl]-1-(4-fluorophenyl)-ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol J Pharmacol Exp Ther 288 1999 1002 1014 (Pubitemid 29254137)
41. H.E. Molewijk, A.M. van der Poel, J. Mos, J.A. van der Heyden, and B. Olivier Conditioned ultrasonic distress vocalizations in adult male rats as a behavioural paradigm for screening anti-panic drugs Psychopharmacology (Berl) 117 1995 32 40
42. J.N. Murthy, and M.R. Pranzatelli Brainstem 5-hydroxytrytamine1A binding sites are not down-regulated by agonists which induce tolerance in the rat: myoclonus and other serotonergic behaviors J Recept Res 12 1992 287 297
43. J.C. Nelson, M.E. Thase, and M.H. Trivedi Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled post hoc analysis (studies CN138-139 and CN138-163) Prim Care Companion J Clin Psychiatry 11 2009 344 352
44. A. Newman-Tancredi, C. Chaput, L. Verriele, and M.J. Millan Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors Neuropharmacology 35 1996 119 121
45. L.S. Pilowsky, H. Ring, P.J. Shine, M. Battersby, and M. Lader Rapid tranquillisation. A survey of emergency prescribing in a general psychiatric hospital Br J Psychiatry 160 1992 831 835
46. J.R. Richards, R.W. Derlet, and D.R. Duncan Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol J Emerg Med 16 1998 567 573 (Pubitemid 28348163)
47. C. Sanchez Stress-induced vocalisation in adult animals. A valid model of anxiety? Eur J Pharmacol 463 2003 133 143 (Pubitemid 36205076)
48. C. Sanchez, J. Arnt, B. Costall, A.M.K.E. Domeney, and R.J. Naylor Sertindole : a limbic selective neuroleptic with potent anxiolytic effects Drug Dev Res 1995 19 29
49. D.J. Sanger, and D. Joly Performance of a passive avoidance response is disrupted by compounds acting at 5HT(1A) receptors Behav Pharmacol 1 1989 235 240
50. D.J. Sanger, D. Joly, and M. LePichon Buspirone, gepirone and ipsapirone disrupt both active and passive avoidance responding in rats Behav Pharmacol 1 1989 153 160
51. B. Scatton, Y. Claustre, A. Cudennec, A. Oblin, G. Perrault, D.J. Sanger, and H. Schoemaker Amisulpride: from animal pharmacology to therapeutic action Int Clin Psychopharmacol 12 Suppl 2 1997 S29 S36
52. R. Schreiber, C. Melon, and V.J. De The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test Psychopharmacology (Berl) 135 1998 383 391 (Pubitemid 28254845)
53. S.G. Siris, and C. Bench Depression and schizophrenia Schizophrenia 2003 Blackwell Oxford 142 167
54. I.H. Slater, G.T. Jones, and R.A. Moore Inhibition of REM sleep by fluoxetine, a specific inhibitor of serotonin uptake Neuropharmacology 17 1978 383 389 (Pubitemid 8356964)
55. J. Stevenson, G.D. Burrows, and E. Chiu Comparison of low doses of haloperidol and diazepam in anxiety states Med J Aust 1 1976 451 452
56. O. Tajima Mental health care in Japan: recognition and treatment of depression and anxiety disorders J Clin Psychiatry 62 Suppl 13 2001 39 44
57. R. Weizman, L. Paz, Y. Peter, and C.G. Pick Mice performance on the staircase test following acute ethanol administration Pharmacol Biochem Behav 68 2001 491 495 (Pubitemid 32452405)
58. C.S. Wilcox, J.M. Ferguson, J.L. Dale, and J.F. Heiser A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients Psychopharmacol Bull 32 1996 335 342 (Pubitemid 26365645)